Paul Stabach
Research Associate 3, MSCards
Additional Titles
Biotechnology Associate
Contact Info
Yale School of Medicine
Department of Pathology, 310 Cedar Street
New Haven, CT 06520
United States
About
Titles
Research Associate 3, MS
Biotechnology Associate
Biography
A Research Associate/Lab Manager with 30 Years of Molecular/Cellular Biological experience from Yale, MIT, Baylor College of Medicine, Jefferson University, and University of Connecticut Health Center, currently focused on the design and implementation of novel enzyme biologics to treat debilitating pathologies associate with enzyme deficiency.
After an initial success in the Braddock lab with a rare disease of lethal vascular calcifications associated with ENPP1 deficiency called 'Generalized Arterial Calcification of Infancy' (GACI), he then published an article detailing how to improve the potency and longevity of any blood based enzyme biologic (Stabach et.al. Clin Transl Sci. 2020 Oct 16). He is now engineering a new enzyme biologic for the treatment of pathologies associate with the aberrant formation of neutrophil extracellular traps, or netosis. If successful, this biologic could have indications with several pathologies including Lupus, Acute Respiratory Distress Syndrome associated with COVID-19, Cancer metastasis, and coagulopathies such as Deep View Thrombosis and Disseminated Intravascular Coagulation.
Appointments
Departments & Organizations
Education & Training
- BS
- University of Connecticut (1984)
Research
Overview
Medical Subject Headings (MeSH)
- View Lab Website
Braddock Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Demetrios Braddock, MD, PhD
Jon Morrow, PhD, MD
Thomas Carpenter, MD
Enrique M. De La Cruz, PhD
Wenxiang Cao, PhD
Joseph Madri, MD/PhD
Publications
Featured Publications
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchAltmetricConceptsSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNA
2024
Novel treatment for PXE: Recombinant ENPP1 enzyme therapy
Jacobs I, Obiri-Yeboah D, Stabach P, Braddock D, Li Q. Novel treatment for PXE: Recombinant ENPP1 enzyme therapy. Molecular Therapy 2024 PMID: 39342427, DOI: 10.1016/j.ymthe.2024.09.028.Peer-Reviewed Original ResearchConceptsAbcc6<sup>-/-</sup> micePseudoxanthoma elasticumAbcc6<sup>-/-</sup> mouse model of pseudoxanthoma elasticumPPi levelsMouse model of pseudoxanthoma elasticumModel of pseudoxanthoma elasticumEnzyme therapyEctopic calcificationPlasma PPi levelsMuzzle skinDose-dependent elevationHepatic efflux transportersPrevent ectopic calcificationPlasma PPiABCC6 geneATP secretionTherapeutic optionsDose-dependentlyEfflux transportersInactivating mutationsENPP1 activitySubcutaneous injectionWeeks of ageNovel treatmentCalcification disordersQuantitative correlation of ENPP1 pathogenic variants with disease phenotype
Ansh A, Stabach P, Ciccone C, Cao W, De La Cruz E, Sabbagh Y, Carpenter T, Ferreira C, Braddock D. Quantitative correlation of ENPP1 pathogenic variants with disease phenotype. Bone 2024, 186: 117136. PMID: 38806089, PMCID: PMC11227391, DOI: 10.1016/j.bone.2024.117136.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEctonucleotide pyrophosphatase/phosphodiesterase 1Pathogenic variantsDisease phenotypeEnzyme velocityCompound heterozygotesEnzyme activityVariable enzyme activityAutosomal dominant phenotypeHigh-throughput assayAutosomal recessive formInnate immune responseENPP1 variantsDamaging variantsENPP1 deficiencyCole diseaseDominant phenotypeAutosomal dominant diseaseCatalytic velocityRecessive formEnzymePhenotypeWT levelsBio-active moleculesClinical phenotypeDominant disease
2022
Outer hair cell function is normal in βV spectrin knockout mice
Stankewich MC, Bai JP, Stabach PR, Khan S, Tan WJT, Surguchev A, Song L, Morrow JS, Santos-Sacchi J, Navaratnam DS. Outer hair cell function is normal in βV spectrin knockout mice. Hearing Research 2022, 423: 108564. PMID: 35864018, DOI: 10.1016/j.heares.2022.108564.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOuter hair cellsAuditory brainstem response wavesAuditory thresholdOuter hair cell functionSpiral ganglion neuronsEfferent nerve fibersHair cell functionNumber of afferentsGanglion neuronsNerve fibersKnockout miceNeuronal structuresMiceHair cellsCell functionElectromechanical activityPutative roleType IOngoing investigationExon deletionsSynaptopathyAfferentsData supportResponse wavesNeuronsResponse of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adults
Ansh A, Nester C, O'Brien C, Stabach P, Murtada S, Lester E, Khursigara G, Molloy L, Carpenter T, Ferreira C, Braddock D. Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adults. The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5311.Peer-Reviewed Original ResearchConceptsENPP1 deficiencyQuality of lifeMusculoskeletal complicationsReplacement therapyBrief Pain Inventory-Short FormPhysical Function Short FormAchilles tendon calcificationHealth-related qualityMajority of patientsCervical spine fusionPresence of enthesopathyAnalgesic medicationRegular chowResidual painAdult patientsDose escalationPhysical functionCardiovascular calcificationTendon calcificationAchilles tendonSpine fusionMurine modelHypophosphatemic ricketsEnzyme replacementPatientsSystematic characterization of enzyme activity on ENPP1 deficiency disease phenotype
Ansh A, Stabach P, Carpenter T, Ferreira C, Braddock D. Systematic characterization of enzyme activity on ENPP1 deficiency disease phenotype. The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5223.Peer-Reviewed Original ResearchStrategies for Glycoengineering Therapeutic Proteins
Dammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ. Strategies for Glycoengineering Therapeutic Proteins. Frontiers In Chemistry 2022, 10: 863118. PMID: 35494652, PMCID: PMC9043614, DOI: 10.3389/fchem.2022.863118.Peer-Reviewed Original ResearchCitationsAltmetric
2021
Placenta-derived interferon-stimulated gene 20 controls ZIKA virus infection
Ding J, Aldo P, Roberts CM, Stabach P, Liu H, You Y, Qiu X, Jeong J, Maxwell A, Lindenbach B, Braddock D, Liao A, Mor G. Placenta-derived interferon-stimulated gene 20 controls ZIKA virus infection. EMBO Reports 2021, 22: embr202152450. PMID: 34405956, PMCID: PMC8490983, DOI: 10.15252/embr.202152450.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsZika virus infectionVirus infectionTrophoblast cellsPotential immune modulatory functionsInterferon-stimulated gene 20Anti-viral treatmentHigh-risk populationImmune modulatory functionsAnti-viral responseZika viral infectionImportance of preventionPregnant womenReplacement therapyViral infectionFetal developmentZika virusViral titersModulatory functionViral replicationInfectionAdverse effectsGene 20PregnancyPlacentaRNA viruses
2020
Musculoskeletal Comorbidities and Quality of Life in ENPP1‐Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine Models
Ferreira CR, Ansh AJ, Nester C, O'Brien C, Stabach PR, Murtada S, Lester ER, Khursigara G, Molloy L, Carpenter TO, Braddock DT. Musculoskeletal Comorbidities and Quality of Life in ENPP1‐Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine Models. Journal Of Bone And Mineral Research 2020, 37: 494-504. PMID: 34882836, PMCID: PMC9667476, DOI: 10.1002/jbmr.4487.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsENPP1 deficiencyAsj/Musculoskeletal complicationsBrief Pain Inventory-Short FormPhysical Function Short FormFibroblast growth factor 23Achilles tendon calcificationHealth-related qualityMajority of patientsGrowth factor 23Cervical spine fusionPresence of enthesopathyQuality of lifeAnalgesic medicationRegular chowResidual painAdult patientsDose escalationFactor 23Replacement therapyPhysical functionCardiovascular calcificationTendon calcificationAchilles tendonSpine fusionCatalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass
Zimmerman K, Liu X, von Kroge S, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass. Journal Of Bone And Mineral Research 2020, 37: 1733-1749. PMID: 35773783, PMCID: PMC9709593, DOI: 10.1002/jbmr.4640.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHeterotopic mineralizationBone massFibroblast growth factor 23Growth factor 23Low bone massSoft tissue calcificationEarly-onset osteoporosisFrizzled-related protein 1Soluble Wnt inhibitorsTrabecular bone microarchitectureENPP1 deficiencyΒ-catenin signalingFactor 23Plasma FGF23Vascular calcificationArterial calcificationNuclear β-cateninPlasma PPiBone microarchitectureMurine modelTissue calcificationPlasma PiWnt inhibitorsCalcificationMice
News
News
Get In Touch
Contacts
Yale School of Medicine
Department of Pathology, 310 Cedar Street
New Haven, CT 06520
United States